Industry reports
Editor highlights

Search inside this page

All regions

Free Market Research Guides to Download

Pathology Industry Market Research Reports, April 2014

You might be interested in: cancer, mental health, cardiovascular disease, more »

» View Public Reports

1-30 of about 12 000 reports

Regeneron Pharmaceuticals Inc. - Company Report for Year 2014

  • Company report
  • April 2014
  • 3 pages
  • by Corporation
  • Industries: Pathology
  • Countries: Japan

U.S. Pharmaceutical Industry Analysis

  • Industry report
  • April 2014
  • 129 pages

... Of work are implicated as important causes of hypertension, as well as cvd., E.G. Job strain 96 schnall pl et al. Why the workplace and cardiovascular disease. In: schnall pl, belkic kl, landsbergis pa ...

  • Industries: Pathology
  • Countries: United States

Company Report: Pathology for Year 2014

  • Company report
  • April 2014
  • 7 pages
  • Industries: Pathology

The Australian Pharmaceutical Business Brief

  • Industry report
  • April 2014
  • 8 pages
  • by Corporation

... To compare the expenditure of other chronic diseases, particularly chronic diseases that share many of the same risk factors such as ckd [14]. As a result, this investigation will determine and compare ...

  • Industries: Pathology
  • Countries: Australia

Lorus Therapeutics Inc. - Company Report for Year 2014

  • Company report
  • April 2014
  • 4 pages
  • Industries: Pathology
  • Countries: Canada, United States

Questcor Pharmaceuticals Inc. - Company Report for Year 2014

  • Company report
  • April 2014
  • 6 pages
  • by Corporation
  • Industries: Pathology
  • Countries: United States

Pharmaceutical Sector in Denmark

  • Industry report
  • April 2014
  • 23 pages
  • by Intergovernmental Agency

... Standardised to the who european standard population although mortality rates for typ. Chronic diseases vary largely, eastern european countries show significant higher motality rates as compared to southern ...

  • Industries: Pathology
  • Countries: Europe, World, Denmark

U.S. Diabete Sector

  • Industry report
  • April 2014
  • 28 pages

... Or insulin, or conventional treatment the ominous octet defronzo r.; diabetes 2009 metformin ampk Glucagon signaling Insulin sensitizer sglt-2 inhibitor insulin insulin sensitizer source ...

  • Industries: Pathology
  • Countries: United States

Company Report: Pathology for Year 2014

  • Company report
  • April 2014
  • 6 pages

... For ampyra in stroke, the adaptive design of the phase 2/3 trial should allow acorda to take an interim look at efficacy as measured by 2-min walk distance as well as a scaled efficacy measurement similar ...

  • Industries: Pathology

Company Report: Cardiovascular Disease for Year 2014

  • Company report
  • April 2014
  • 9 pages
  • Industries: Pathology

Johnson and Johnson - Company Report for Year 2014

  • Company report
  • April 2014
  • 9 pages
  • by Corporation

... Hepatitis c in adult patients; siltuximab for the treatment of adult patients with multicentric castleman's disease who are hiv-negative and human herpes virus-8 negative; and vokanamet , a fixed ...

  • Industries: Pathology
  • Countries: United States

The United States: Demographic Analysis, 2014-2017

  • Country report
  • April 2014
  • 50 pages

... Related diseases to account for the low life expectancy and queried whether figures may improve, the longer the industry ceases to exist. In response, the director of public health confirmed that we could ...

  • Industries: Pathology
  • Countries: United States

Company Report: Pathology in Australia for Year 2014

  • Company report
  • March 2014
  • 7 pages

... Are picked up and treated before permanent damage is done, ms clark said. If caught early, those affected may only need to make small lifestyle changes in order to prevent further loss, such as turning ...

  • Industries: Pathology
  • Countries: Australia

The Australian Pharmaceutical Industry Brief

  • Industry report
  • March 2014
  • 18 pages
  • Industries: Pathology
  • Countries: Australia

Medical Technology Stock Letter - Company Report for Year 2014

  • Company report
  • March 2014
  • 9 pages

... More positive ones . Bmy announced a broad phase iii program for pd-1 in lung cancer, right before reporting outstanding two-year survival data for the checkpoint inhibitor drug in late- stage ...

  • Industries: Pathology
  • Countries: United States

Company Report: Pathology in The United States, France and Belgium for Year 2014

  • Company report
  • March 2014
  • 2 pages

... From mild skin rashes to severe organ failure to death. In addition to the significant suffering to patients, the socioeconomic burden of just rheumatoid arthritis has been estimated at ~$40bn ...

  • Industries: Pathology
  • Countries: United States, France, Belgium

Company Report: Pathology in The United States for Year 2014

  • Company report
  • March 2014
  • 25 pages
  • Industries: Pathology
  • Countries: United States

Athersys Inc. - Company Report for Year 2014

  • Company report
  • March 2014
  • 2 pages
  • by Corporation

... By myocardial infarction, and for the prevention of graft-versus-host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has ...

  • Industries: Pathology
  • Countries: United States

Company Report: Pathology in The United States and Australia for Year 2014

  • Company report
  • March 2014
  • 3 pages

... cold. There is a theory that spontaneous remission in some cancer patients has potentially been due to infection of the common cold. The results from the phase ii study have been very impressive ...

  • Industries: Pathology
  • Countries: United States, Australia

Pharmaceutical Sector in New Zealand

  • Industry report
  • March 2014
  • 43 pages
  • Industries: Pathology
  • Countries: New Zealand

Company Report: Pathology in Israel and The United States for Year 2014

  • Company report
  • March 2014
  • 85 pages
  • by Corporation

... That we expend significant funds and will be subject to the risks of failure inherent in the development of pharmaceutical products. In order to successfully commercialize any of our therapeutic cands ...

  • Industries: Pathology
  • Countries: Israel, United States

Company Report: Dementia in The United Kingdom for Year 2014

  • Company report
  • March 2014
  • 7 pages

... To deliver high quality dementia care. Moreover, as the number at risk of dementia increases as the population ages, such problems are only going to get worse. Is it fair to blame local authorities ...

  • Industries: Pathology
  • Countries: United Kingdom

Company Report: Pathology for Year 2014

  • Company report
  • March 2014
  • 27 pages
  • Industries: Pathology

Company Report: Pathology in The United States and Israel for Year 2014

  • Company report
  • March 2014
  • 36 pages
  • Industries: Pathology
  • Countries: United States, Israel

Company Report: Pathology in The United States and Germany for Year 2014

  • Company report
  • March 2014
  • 21 pages

... By activaero vectura strategic priorities products focused on airways diseases balanced pipeline breadth of enabling technologies revenue-generating assets near-to-market products opportunities for self ...

  • Industries: Pathology
  • Countries: United States, World, Germany

Company Report: Pathology in India and The United States for Year 2014

  • Company report
  • March 2014
  • 3 pages
  • Industries: Pathology
  • Countries: India, United States

U.S. Prostate Cancer Sector

  • Industry report
  • March 2014
  • 40 pages

... And respiratory infections. The vitamin d-sensitive diseases that account for more than half of global mortality rates are cvd, cancer, respiratory infections, respiratory diseases, tuberculosis and diabetes ...

  • Industries: Pathology
  • Countries: United States

Company Report: Pathology for Year 2014

  • Company report
  • March 2014
  • 5 pages
  • Industries: Pathology

Company Report: Cancer in The United States for Year 2014

  • Company report
  • March 2014
  • 4 pages

... At montefiore einstein center for cancer care in new york, and moffit cancer center in tampa, florida. This trial will be conducted with leading breast cancer expert dr. Joseph sparano as principal ...

  • Industries: Pathology
  • Countries: United States

Company Report: Pathology in Canada for Year 2014

  • Company report
  • March 2014
  • 38 pages
  • by Governmental Agency
  • Industries: Pathology
  • Countries: Canada

» Purchase Premium Reports (From $ 75 - $ 9 995)

About 5 600 reports
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked ...

Russia Hiv/aids, Dalys

May 2013 $ 250

Cyprus Hiv/aids, Dalys

May 2013 $ 250

Gambia Gonorrhoea, Dalys

May 2013 $ 250

Angola Syphilis, Dalys

May 2013 $ 250

Moldova Chlamydia, Dalys

May 2013 $ 250

Bahamas Gonorrhoea, Dalys

May 2013 $ 250

» Read our Company Profiles

33 Companies

EDGAR Online Inc.

United States

Roche Holding AG

Switzerland

Johnson and Johnson

United States

AccessEd

Australia

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.